Clinical Trials Browser

Phase 2 × pazopanib × Genitourinary × Clear all

NCT01217931 2026-01-30

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07087158 2025-07-28

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT01147822 2025-03-28

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2 Completed

367 enrolled 14 charts

Carcinoma, Renal Cell

NCT01767636 2025-03-03

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

38 enrolled 12 charts

Oncocytoma, renal, Carcinoma, Renal Cell

NCT03200717 2023-08-21

IO-PAZ

Phase 2 Completed

62 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01157091 2022-06-08

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Phase 2 Completed

28 enrolled 10 charts

Carcinoma, Renal Cell

NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Phase 2 Completed

41 enrolled 13 charts

Carcinoma, Renal Cell

NCT03334409 2022-03-31

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 2 Terminated

5 enrolled 16 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT01566747 2021-12-23

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5

Phase 2 Completed

Carcinoma, Renal Cell

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

69 enrolled 15 charts

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT02959554 2021-09-08

NIVOSWITCH

Phase 2 Terminated

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01743482 2021-05-14

Pazotest-01

Phase 2 Completed

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT02960906 2021-04-26

BIONIKK

Phase 2 Completed

Clear-cell metastatic renal cell carcinoma

NCT04462445 2020-07-10

PIPELINE

Phase 2 Completed

Carcinoma, Renal Cell

NCT02187302 2020-05-28

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Phase 2 Completed

Carcinoma, Renal Cell

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT03379012 2019-10-22

FARETES

Phase 2 Completed

Carcinoma, Renal Cell

NCT01731158 2019-02-06

BERAT

Phase 2 Completed

Carcinoma, Renal Cell

NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Phase 2 Completed

30 enrolled 10 charts

Adenocarcinoma of the Prostate

NCT02560012 2018-10-12

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2 Terminated

4 enrolled 3 charts

Carcinoma, Renal Cell

NCT01158521 2018-09-12

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Phase 2 Completed

25 enrolled 8 charts

Carcinoma, Renal Cell

NCT01361113 2018-04-25

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Phase 2 Completed

21 enrolled 10 charts

Carcinoma, Renal Cell

NCT01622660 2017-08-22

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Phase 2 Terminated

2 enrolled 9 charts

Urinary Bladder Neoplasms

NCT02089802 2017-08-18

OPERA

Phase 2 Terminated

Carcinoma, Renal Cell

NCT01108055 2017-06-09

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Phase 2 Completed

43 enrolled 16 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00486642 2017-05-24

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

23 enrolled 14 charts

Prostatic Neoplasms

NCT00244764 2017-03-27

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Completed

225 enrolled 10 charts

Carcinoma, Renal Cell

NCT00256880 2017-01-18

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Phase 2 Completed

GenitourinaryPlasma cell

Carcinoma, Renal Cell, Neoplasms, Plasma Cell

NCT00454571 2016-02-10

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Phase 2 Completed

37 enrolled 5 charts

Prostatic Neoplasms

NCT00731211 2015-05-20

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Phase 2 Completed

57 enrolled 6 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT02324803 2014-12-24

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Phase 2 Unknown

Carcinoma, Renal Cell, Drug-Related Side Effects and Adverse Reactions

NCT01408004 2014-07-16

ROPETAR

Phase 2 Completed

Carcinoma, Renal Cell

NCT00471536 2014-05-30

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Phase 2 Completed

19 enrolled 8 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01577784 2014-03-12

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

Phase 2 Unknown

Carcinoma, Renal Cell

NCT00945477 2013-11-18

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Phase 2 Terminated

11 enrolled 6 charts

Prostatic Neoplasms